Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE +/- Sorafenib in HCC with Microvascular Invasion
NCT02436902Phase 3Unknown
- Sponsor
- Guangxi Medical University
- Start
- Feb 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02436902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436902.